Settlement Gives Celltrion Date For US Higher-Strength Humira Biosimilar

Plans Q3 2023 Launch For Yuflyma 100mg/ml Citrate-Free Version Of Adalimumab

 
• By Dave Wallace

Celltrion has secured a US launch date for its higher-strength adalimumab biosimilar, Yuflyma, through a settlement with AbbVie. However, the company will face a number of other Humira rivals in 2023.

Queue line of wooden people waiting
Celltrion has joined a number of other Humira biosimilar sponsors waiting for launch in 2023 • Source: Roman Samborskyi / Alamy Stock Photo

More from Legal & IP

More from Generics Bulletin